Kestra Medical Technologies reported a gross margin of 54.76% and a net margin of -135.61% for the quarter ended Apr 2026. These financial ratios cover 10 quarters of results from Jan 2024 through Apr 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross Margin | 10.63% | 13.89% | 32.86% | 39.63% | 43.39% | 44.29% | 45.69% | 50.63% | 52.57% | 54.76% |
| EBT Margin | -261.02% | -221.91% | -158.94% | -140.13% | -144.08% | -296.00% | -133.15% | -145.14% | -139.02% | -134.94% |
| EBIT Margin | -240.98% | -202.40% | -144.19% | -130.07% | -136.52% | -279.77% | -149.08% | -140.73% | -141.60% | -137.38% |
| EBITDA Margin | -240.98% | -202.40% | -144.19% | -130.07% | -136.52% | -279.77% | -149.08% | -140.73% | -141.60% | -137.38% |
| Operating Margin | -240.98% | -202.40% | -144.19% | -130.07% | -136.52% | -279.77% | -149.08% | -140.73% | -141.60% | -137.38% |
| Net Margin | -283.09% | -241.48% | -174.21% | -161.05% | -164.57% | -321.15% | -133.32% | -145.29% | -139.16% | -135.61% |
| FCF Margin | -189.55% | -191.96% | -152.98% | -146.19% | -182.47% | -177.79% | -113.49% | -114.71% | -99.11% | |
| Efficiency | ||||||||||
| Assets AverageAssets Avg. | 201.87M | 281.02M | 256.50M | 313.02M | 368.90M | |||||
| Invested CapitalInvested Cap. | -166.84M | -214.15M | 246.50M | 225.65M | 205.95M | 330.25M | 302.31M | |||
| Asset Utilization RatioAsset Util. | 0.30 | 0.24 | 0.29 | 0.27 | 0.26 | |||||
| Leverage & Solvency | ||||||||||
| Interest Coverage RatioInterest Cover | -12.08 | -10.52 | -9.84 | -8.26 | -11.55 | -27.39 | -15.10 | -16.70 | -18.41 | -21.34 |
| Debt Ratio | 0.93 | 0.41 | 0.14 | 0.16 | 0.17 | 0.11 | 0.12 | |||
| Times Interest Earned | -12.08 | -10.52 | -9.84 | -8.26 | -11.55 | -27.39 | -15.10 | -16.70 | -18.41 | -21.34 |
| Valuation | ||||||||||
| Price to EarningsP/E | -10.69 | -32.81 | -42.97 | -42.13 | -31.15 | |||||
| Price to SalesP/S | 34.32 | 43.74 | 62.43 | 58.63 | 42.24 | |||||
| Price to BookP/B | 2.88 | 4.60 | 8.59 | 5.00 | 4.66 | |||||
| Enterprise Value | 353.89M | 646.04M | 1,233.25M | 1,148.15M | 850.79M | |||||
| EV to EBIT | -7.34 | -22.37 | -38.84 | -33.03 | -21.62 | |||||
| EV to EBITDA | -7.34 | -22.37 | -38.84 | -33.03 | -21.62 | |||||
| Market Capitalization | 591.48M | 847.25M | 1,408.68M | 1,439.47M | 1,209.71M | |||||
| Price to FCFP/FCF | -18.81 | -24.60 | -55.01 | -51.11 | -42.62 | |||||
| EV to FCF | -11.25 | -18.76 | -48.16 | -40.77 | -29.97 | |||||
| EV to CFO | -14.71 | -24.59 | -67.23 | -62.51 | -45.45 | |||||
| Return Ratios | ||||||||||
| Return on Sales [ROS]ROS | -240.98% | -202.40% | -144.19% | -130.07% | -136.52% | -279.77% | -149.08% | -140.73% | -141.60% | -137.38% |
| Return on Capital Employed [ROCE]ROCE | -64.91% | -46.96% | -58.64% | -53.17% | -42.30% | |||||
| Return on Invested Capital [ROIC]ROIC | -493.13% | -37.69% | -47.02% | -43.00% | -42.70% | |||||
| Return on Assets [ROA]ROA | -42.23% | -32.30% | -40.13% | -36.85% | -35.68% |